159 related articles for article (PubMed ID: 22806683)
21. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
22. Therapy for Alopecia Areata in Mice by Stimulating the Hair Cycle with Parathyroid Hormone Agonists Linked to a Collagen-Binding Domain.
Katikaneni R; Seymour AW; Gulati R; Ponnapakkam T; Gensure RC
J Investig Dermatol Symp Proc; 2015 Nov; 17(2):13-5. PubMed ID: 26551937
[TBL] [Abstract][Full Text] [Related]
23. Role of parathyroid hormone therapy in reversing radiation-induced nonunion and normalization of radiomorphometrics in a murine mandibular model of distraction osteogenesis.
Gallagher KK; Deshpande S; Tchanque-Fossuo CN; Donneys A; Sarhaddi D; Nelson NS; Chepeha DB; Buchman SR
Head Neck; 2013 Dec; 35(12):1732-7. PubMed ID: 23335324
[TBL] [Abstract][Full Text] [Related]
24. Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.
Schafer AL; Sellmeyer DE; Palermo L; Hietpas J; Eastell R; Shoback DM; Black DM
J Clin Endocrinol Metab; 2012 Oct; 97(10):3522-9. PubMed ID: 22791766
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct.
Stratford R; Vu C; Sakon J; Katikaneni R; Gensure R; Ponnapakkam T
J Pharm Sci; 2014 Feb; 103(2):768-75. PubMed ID: 24399637
[TBL] [Abstract][Full Text] [Related]
26. The anabolic response to parathyroid hormone is augmented in Rac2 knockout mice.
Kawano T; Troiano N; Adams DJ; Wu JJ; Sun BH; Insogna K
Endocrinology; 2008 Aug; 149(8):4009-15. PubMed ID: 18467443
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of periosteal bone formation by basic fibroblast-derived growth factor containing polycystic kidney disease and collagen-binding domains from Clostridium histolyticum collagenase.
Uchida K; Matsushita O; Nishi N; Inoue G; Horikawa K; Takaso M
J Tissue Eng Regen Med; 2017 Apr; 11(4):1165-1172. PubMed ID: 25783848
[TBL] [Abstract][Full Text] [Related]
28. Adult-Onset Deletion of β-Catenin in (10kb)Dmp1-Expressing Cells Prevents Intermittent PTH-Induced Bone Gain.
Kedlaya R; Kang KS; Hong JM; Bettagere V; Lim KE; Horan D; Divieti-Pajevic P; Robling AG
Endocrinology; 2016 Aug; 157(8):3047-57. PubMed ID: 27253995
[TBL] [Abstract][Full Text] [Related]
29. Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy.
Sinha P; Aarnisalo P; Chubb R; Poulton IJ; Guo J; Nachtrab G; Kimura T; Swami S; Saeed H; Chen M; Weinstein LS; Schipani E; Sims NA; Kronenberg HM; Wu JY
J Biol Chem; 2016 Jan; 291(4):1631-1642. PubMed ID: 26598522
[TBL] [Abstract][Full Text] [Related]
30. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.
Horwitz MJ; Tedesco MB; Gundberg C; Garcia-Ocana A; Stewart AF
J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182
[TBL] [Abstract][Full Text] [Related]
31. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
32. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
33. Effect of intermittent administration of human parathyroid hormone on bone mineral density and arthritis in rats with collagen-induced arthritis.
Fukata S; Hagino H; Okano T; Yamane I; Kameyama Y; Teshima R
Arthritis Rheum; 2004 Dec; 50(12):4060-9. PubMed ID: 15593226
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice.
Samadfam R; Xia Q; Goltzman D
Endocrinology; 2007 Jun; 148(6):2778-87. PubMed ID: 17379647
[TBL] [Abstract][Full Text] [Related]
35. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats.
Schmitt CP; Hessing S; Oh J; Weber L; Ochlich P; Mehls O
Kidney Int; 2000 Apr; 57(4):1484-92. PubMed ID: 10760084
[TBL] [Abstract][Full Text] [Related]
36. Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion.
Fox J; Miller MA; Stroup GB; Nemeth EF; Miller SC
Bone; 1997 Aug; 21(2):163-9. PubMed ID: 9267692
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
Shen L; Xie X; Su Y; Luo C; Zhang C; Zeng B
PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.
Hodsman AB; Hanley DA; Ettinger MP; Bolognese MA; Fox J; Metcalfe AJ; Lindsay R
J Clin Endocrinol Metab; 2003 Nov; 88(11):5212-20. PubMed ID: 14602752
[TBL] [Abstract][Full Text] [Related]
39. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
Walker EC; Poulton IJ; McGregor NE; Ho PW; Allan EH; Quach JM; Martin TJ; Sims NA
J Bone Miner Res; 2012 Apr; 27(4):902-12. PubMed ID: 22190112
[TBL] [Abstract][Full Text] [Related]
40. Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice.
Iida-Klein A; Lu SS; Kapadia R; Burkhart M; Moreno A; Dempster DW; Lindsay R
J Endocrinol; 2005 Sep; 186(3):549-57. PubMed ID: 16135674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
